相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations
Batra Ullas et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)
Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy
Qingqing Pan et al.
MOLECULAR PHARMACEUTICS (2023)
Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine derivatives as novel EGFRL858R/T790M inhibitors
Jianfang Fu et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2023)
Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs
Dongyu Li et al.
BIOMEDICINES (2023)
Combining structure-based and 3D QSAR pharmacophore models to discover diverse ligands against EGFR in oral cancer
Purbali Chakraborty et al.
FUTURE MEDICINAL CHEMISTRY (2022)
Building 2D classification models and 3D CoMSIA models on small-molecule inhibitors of both wild-type and T790M/L858R double-mutant EGFR
Donghui Huo et al.
MOLECULAR DIVERSITY (2022)
PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis
Yu He et al.
CELL DEATH & DISEASE (2022)
Ubiquitination and SUMOylation: protein homeostasis control over cancer
Xiaofeng Dai et al.
EPIGENOMICS (2022)
PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal Cancer
Maochao Luo et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2022)
Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
Krishna Babu Duggirala et al.
BIOMOLECULES & THERAPEUTICS (2022)
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
Sanjay Popat et al.
ONCOLOGIST (2022)
Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/ T790M/C797S forms of EGFR
Duangjai Todsaporn et al.
COMPUTERS IN BIOLOGY AND MEDICINE (2022)
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer
Meredith S. Eno et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives
Tobias Boch et al.
CANCER BIOLOGY & MEDICINE (2022)
FGFR1 SUMOylation coordinates endothelial angiogenic signaling in angiogenesis
Xiaolong Zhu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis
Xun Shangguan et al.
NATURE COMMUNICATIONS (2021)
Targeting SUMOylation in cancer
Li Du et al.
CURRENT OPINION IN ONCOLOGY (2021)
Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer
Ting Li et al.
CELL DEATH & DISEASE (2021)
SUMOylation modification-mediated cell death
Zenghua Sheng et al.
OPEN BIOLOGY (2021)
Annexin A6 improves anti-migratory and anti-invasive properties of tyrosine kinase inhibitors in EGFR overexpressing human squamous epithelial cells
Monira Hoque et al.
FEBS JOURNAL (2020)
TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target
Jiao-jiao Yu et al.
NATURE COMMUNICATIONS (2020)
SUMOylation stabilizes hSSB1 and enhances the recruitment of NBS1 to DNA damage sites
Liwen Zhou et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways
Yanfang Yang et al.
CELL COMMUNICATION AND SIGNALING (2019)
MS-based strategies for identification of protein SUMOylation modification
Zenghua Sheng et al.
ELECTROPHORESIS (2019)
Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models
Ioanna Keklikoglou et al.
NATURE CELL BIOLOGY (2019)
Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy
Zhe Zhang et al.
THERANOSTICS (2019)
Downregulation of caveolin-1 increased EGFR-TKIs sensitivity in lung adenocarcinoma cell line with EGFR mutation
Yujie Cui et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
EGFR-TKIs resistance via EGFR-independent signaling pathways
Qian Liu et al.
MOLECULAR CANCER (2018)
Small-Molecule Inhibitors Targeting Protein SUMOylation as Novel Anticancer Compounds
Yanfang Yang et al.
MOLECULAR PHARMACOLOGY (2018)
BACE1 SUMOylation increases its stability and escalates the protease activity in Alzheimer's disease
Jian Bao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
SILAC-based quantitative MS approach for real-time recording protein-mediated cell-cell interactions
Xixi Wang et al.
SCIENTIFIC REPORTS (2018)
Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy
Md. Habban Akhter et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
A SUMO-ubiquitin relay recruits proteasomes to chromosome axes to regulate meiotic recombination
H. B. D. Prasada Rao et al.
SCIENCE (2017)
Annexin A6A multifunctional scaffold in cell motility
Thomas Grewal et al.
CELL ADHESION & MIGRATION (2017)
Protein SUMOylation modification and its associations with disease
Yanfang Yang et al.
OPEN BIOLOGY (2017)
SUMOylation of IQGAP1 promotes the development of colorectal cancer
Ziwei Liang et al.
CANCER LETTERS (2017)
A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer
Dermot O'Sullivan et al.
BRITISH JOURNAL OF CANCER (2017)
SUMOylation of large tumor suppressor 1 at Lys751 attenuates its kinase activity and tumor-suppressor functions
Liu Mei et al.
CANCER LETTERS (2017)
Annexin A6 and Late Endosomal Cholesterol Modulate Integrin Recycling and Cell Migration
Ana Garcia-Melero et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Review on EGFR Inhibitors: Critical Updates
Davinder Singh et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2016)
Diagnosing inflammation and infection in the urinary system via proteomics
Yanbao Yu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Proteome-wide identification of SUMO modification sites by mass spectrometry
Triin Tammsalu et al.
NATURE PROTOCOLS (2015)
SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1
Yingying Qu et al.
MOLECULAR CANCER (2014)
Epidermal growth factor receptor targeting in cancer: A review of trends and strategies
Chetan Yewale et al.
BIOMATERIALS (2013)
Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors
Rainelli B. Koumangoye et al.
MOLECULAR CANCER (2013)
Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations
T. Yamada et al.
ONCOGENE (2013)
Annexin A6 is a scaffold for PKCα to promote EGFR inactivation
M. Koese et al.
ONCOGENE (2013)
Annexin A6 contributes to the invasiveness of breast carcinoma cells by influencing the organization and localization of functional focal adhesions
Amos M. Sakwe et al.
EXPERIMENTAL CELL RESEARCH (2011)
Annexin A6 inhibits Ras signalling in breast cancer cells
S. Vila de Muga et al.
ONCOGENE (2009)
Annexin A6 stimulates the membrane recruitment of p120GAP to modulate Ras and Raf-1 activity
T Grewal et al.
ONCOGENE (2005)
Dysregulation of the annexin family protein family is associated with prostate cancer progression
W Xin et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia
JS Chen et al.
BLOOD (2001)
分享论文
